{"id":9819,"date":"2025-08-21T11:17:40","date_gmt":"2025-08-21T09:17:40","guid":{"rendered":"https:\/\/www.cebio-med.com\/?page_id=9819"},"modified":"2025-09-29T11:12:54","modified_gmt":"2025-09-29T09:12:54","slug":"publikationen","status":"publish","type":"page","link":"https:\/\/cebio-med.de\/en\/publikationen\/","title":{"rendered":"Publications"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Publications<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

CEBIO regularly contributes to publications on liquid biopsy, reference materials, and molecular diagnostics.<\/p>\n

Please select from the list or browse our latest contributions.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n
contact<\/div>\n
contacts<\/div>\n
found<\/div>\n
\n
\n
<\/div>\n

<\/p>\n

<\/form>\n<\/div>\n
<\/div>\n

file found.<\/span>files found.<\/span><\/p>\n

No files found.<\/div>\n
\n
\n
\n
\n
File<\/span><\/div>\n
Publication<\/span><\/div>\n
Reference<\/span><\/div>\n
Category<\/span><\/div>\n
de|en<\/span><\/div>\n<\/div>\n
\n
Materials for Liquid Biopsy Quality Assurance<\/a>2.06 MB<\/span><\/p>\n

Simon K, Uhlig C, J\u00e4hne M, Uhlig S, Holdenrieder S, Bronkhorst A Market-Ready Cell Line-derived cfDNA Reference Materials for Liquid Biopsy Quality Assurance<\/p>\n

<\/span><\/div>\n

TriCon 2025, Boston<\/span><\/div>\n
<\/span><\/div>\n
<\/p>\n
Posters<\/span>Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy<\/a>1.00 MB<\/span><\/p>\n

Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy.<\/p>\n

<\/span><\/div>\n

Tumor Biol, 2023 in press<\/span><\/div>\n
https:\/\/doi.org\/10.3233\/tub-230015<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients \u2013 a CEPAC-TDM biomarker substudy<\/a>1.19 MB<\/span><\/p>\n

Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients \u2013 a CEPAC-TDM biomarker substudy.<\/p>\n

<\/span><\/div>\n

Tumor Biol, 2023 in press<\/span><\/div>\n
https:\/\/doi.org\/10.3233\/tub-230014<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Method comparison and clinical performance of breast cancer tumor markers on novel multiplex immunoassay and automatized LOCI technology platforms<\/a>2.13 MB<\/span><\/p>\n

Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.<\/p>\n

<\/span><\/div>\n

Diagnostics 2023, 13, 3101<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/diagnostics13193101<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-\u03b3, TNF-\u03b1 and PD-1\/PD-L1 in comparison to established serum tumor markers<\/a>1.53 MB<\/span><\/p>\n

Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-\u03b3, TNF-\u03b1 and PD-1\/PD-L1 in comparison to established serum tumor markers.<\/p>\n

<\/span><\/div>\n

J Cancer Res Clin Oncol 2022<\/span><\/div>\n
https:\/\/doi.org\/10.1007\/s00432-022-04112-z<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancies<\/a>0.98 MB<\/span><\/p>\n

Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie<\/p>\n

<\/span><\/div>\n

Biomedicines 2023; 11: 2960<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/biomedicines11112960<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies<\/a>1.65 MB<\/span><\/p>\n

Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.\u00a0<\/p>\n

<\/span><\/div>\n

Cancers 2023, 15: 5081<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/cancers15205081<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Diagnostic potential of exosomal microRNAs in colorectal cancer<\/a>1.41 MB<\/span><\/p>\n

Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.<\/p>\n

<\/span><\/div>\n

Diagnostics 2022 Jun 8;12(6):1413<\/span><\/div>\n
https:\/\/do.org\/10.3390\/diagnostics12061413<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Multi Omic Candidate Screening for Markers of Severe Clinical Courses of COVID19<\/a>1.22 MB<\/span><\/p>\n

Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19<\/p>\n

<\/span><\/div>\n

J Clin Med 2023; 12, 6225<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/jcm12196225<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n<\/div>\n

<\/div>\n<\/div>\n
\n
\n
\n
\n
File<\/span><\/div>\n
Publication<\/span><\/div>\n
Reference<\/span><\/div>\n
Category<\/span><\/div>\n
de|en<\/span><\/div>\n<\/div>\n
\n
Materials for Liquid Biopsy Quality Assurance<\/a>2.06 MB<\/span><\/p>\n

Simon K, Uhlig C, J\u00e4hne M, Uhlig S, Holdenrieder S, Bronkhorst A Market-Ready Cell Line-derived cfDNA Reference Materials for Liquid Biopsy Quality Assurance<\/p>\n

<\/span><\/div>\n

TriCon 2025, Boston<\/span><\/div>\n
<\/span><\/div>\n
<\/p>\n
Posters<\/span>Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy<\/a>1.00 MB<\/span><\/p>\n

Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy.<\/p>\n

<\/span><\/div>\n

Tumor Biol, 2023 in press<\/span><\/div>\n
https:\/\/doi.org\/10.3233\/tub-230015<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients \u2013 a CEPAC-TDM biomarker substudy<\/a>1.19 MB<\/span><\/p>\n

Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients \u2013 a CEPAC-TDM biomarker substudy.<\/p>\n

<\/span><\/div>\n

Tumor Biol, 2023 in press<\/span><\/div>\n
https:\/\/doi.org\/10.3233\/tub-230014<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Method comparison and clinical performance of breast cancer tumor markers on novel multiplex immunoassay and automatized LOCI technology platforms<\/a>2.13 MB<\/span><\/p>\n

Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.<\/p>\n

<\/span><\/div>\n

Diagnostics 2023, 13, 3101<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/diagnostics13193101<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-\u03b3, TNF-\u03b1 and PD-1\/PD-L1 in comparison to established serum tumor markers<\/a>1.53 MB<\/span><\/p>\n

Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-\u03b3, TNF-\u03b1 and PD-1\/PD-L1 in comparison to established serum tumor markers.<\/p>\n

<\/span><\/div>\n

J Cancer Res Clin Oncol 2022<\/span><\/div>\n
https:\/\/doi.org\/10.1007\/s00432-022-04112-z<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancies<\/a>0.98 MB<\/span><\/p>\n

Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie<\/p>\n

<\/span><\/div>\n

Biomedicines 2023; 11: 2960<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/biomedicines11112960<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies<\/a>1.65 MB<\/span><\/p>\n

Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.\u00a0<\/p>\n

<\/span><\/div>\n

Cancers 2023, 15: 5081<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/cancers15205081<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Diagnostic potential of exosomal microRNAs in colorectal cancer<\/a>1.41 MB<\/span><\/p>\n

Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.<\/p>\n

<\/span><\/div>\n

Diagnostics 2022 Jun 8;12(6):1413<\/span><\/div>\n
https:\/\/do.org\/10.3390\/diagnostics12061413<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n

\n
Multi Omic Candidate Screening for Markers of Severe Clinical Courses of COVID19<\/a>1.22 MB<\/span><\/p>\n

Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19<\/p>\n

<\/span><\/div>\n

J Clin Med 2023; 12, 6225<\/span><\/div>\n
https:\/\/doi.org\/10.3390\/jcm12196225<\/span><\/div>\n
<\/p>\n
Publications<\/span><\/div>\n

<\/span><\/div>\n

<\/p>\n
en<\/span><\/div>\n

<\/span><\/div>\n<\/div>\n<\/div>\n

<\/div>\n<\/div>\n<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

« BackMulti Omic Candidate Screening for Markers of Severe Clinical Courses of COVID191.22 MB27. August 2025PublikationenenVer\u00f6ffentlichung J Clin Med 2023; 12, 6225Externer Link https:\/\/doi.org\/10.3390\/jcm12196225Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19Publikationen CEBIO […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-9819","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/pages\/9819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/comments?post=9819"}],"version-history":[{"count":10,"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/pages\/9819\/revisions"}],"predecessor-version":[{"id":10793,"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/pages\/9819\/revisions\/10793"}],"wp:attachment":[{"href":"https:\/\/cebio-med.de\/en\/wp-json\/wp\/v2\/media?parent=9819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}